Gelesis (GLS) Stock Price, News & Analysis

Company Overview

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.11 to $0.33
• 52-Week Range: N/A
• Volume: 185,100 shs
• Average Volume: 386,034 shs
• Market Capitalization: $11.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GLS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Gelesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gelesis investors own include VIQ Solutions (VQS), Faraday Future Intelligent Electric (FFIE), Eos Energy Enterprises (EOSE), Danimer Scientific (DNMR), Crown ElectroKinetics (CRKN), Boxed (BOXD) and BitNile Metaverse (BNMV).

Company Calendar

• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:GLS
• CIK: 1805087
• Web: www.gelesis.com
• Phone: N/A
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-56,030,000.00
• Net Margins: -221.38%
• Pretax Margin: -214.62%
• Return on Equity: N/A
• Return on Assets: -14.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $25.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.34) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 73,333,000
• Free Float: 64,606,000
• Market Cap: $11.63 million
• Optionable: Not Optionable
• Beta: 0.88